Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality.

[1]  D. Blumenthal,et al.  National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. , 1997, Archives of internal medicine.

[2]  L. Erhardt,et al.  Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. , 1995, European heart journal.

[3]  M. Drazner,et al.  Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. , 2001, Journal of the American College of Cardiology.

[4]  C B Granger,et al.  Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. , 1999, European heart journal.

[5]  M. Packer,et al.  Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. , 1986, Circulation.

[6]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[7]  H. Krumholz,et al.  Quality of care for patients hospitalized with heart failure at academic medical centers. , 1999, American heart journal.

[8]  G. Couper,et al.  Target heart failure populations for newer therapies. , 1995, Circulation.

[9]  C. O'connor,et al.  Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. , 1997, The American journal of cardiology.

[10]  J. Feinglass,et al.  Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. , 1997, American heart journal.

[11]  M. Pfeffer,et al.  Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. , 2000, The American journal of medicine.

[12]  B. Uretsky,et al.  Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? , 1997, Journal of the American College of Cardiology.

[13]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[14]  M. Malone.  Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. , 1997, Archives of internal medicine.

[15]  S. Yusuf,et al.  Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. , 1994, American heart journal.

[16]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[17]  W. Xian.  Primary Prevention of Sudden Cardiac Death in Heart Failure , 2001 .

[18]  K. Parker,et al.  Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. , 1998, Archives of internal medicine.

[19]  W. Stevenson,et al.  Increased risk of progressive hemodynamic deterioration in advanced heart failure patients requiring permanent pacemakers. , 1993, American heart journal.

[20]  S. Tretli,et al.  Female sex as an important determinant of lisinopril-induced cough , 1992, The Lancet.

[21]  J. Hansen,et al.  Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. , 1994, European heart journal.

[22]  B. W. East,et al.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. , 1985, British heart journal.

[23]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[24]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[25]  B. Massie,et al.  Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. , 1997, Journal of the American College of Cardiology.

[26]  Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators. , 1996, Archives of internal medicine.

[27]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[28]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[29]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[30]  L. Tavazzi,et al.  Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). , 2002, American heart journal.

[31]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[32]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[33]  A. Crisp.  'Biological' depression; because sleep fails? , 1986, Postgraduate medical journal.

[34]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.

[35]  S. Gottlieb,et al.  Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. , 1986, Postgraduate medical journal.

[36]  H. Krumholz,et al.  Quality of care for elderly patients hospitalized with heart failure. , 1997, Archives of internal medicine.

[37]  M B Weiss,et al.  Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. , 1996, American heart journal.

[38]  J. Vítovec,et al.  Noninvasive prognostic factors in chronic heart failure , 1995 .